18 and older, any sex, with Substance Use Disorders. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Reach: As Assessed by the Mean Number of Clinics With Participants Who Download the A-CHESS AppPrimary· 45 months
The mean number of clinics with patients who download the A-CHESS app will be obtained monthly during the study via the A-CHESS server and Iowa Department of Public Health (IDPH) data.
Group
Value
95% CI
TAU/Control
0.039
± 0.029
NIATx-TI Framework
0.171
± 0.041
Reach: As Assessed by the Number of Days That Participants Use the A-CHESSPrimary· 45 months
The frequency of use of A-CHESS by each participant will be obtained monthly during the study via the A-CHESS server and Iowa Department of Public Health (IDPH) data.
Group
Value
95% CI
TAU/Control
0.161
± 0.466
NIATx-TI Framework
1.845
± 1.487
Adoption: Number of Days Each Counselor Used the A-CHESSSecondary· 45 months
Number of days each counselor used the A-CHESS will be assessed by A-CHESS logs
Group
Value
95% CI
TAU/Control
1.81
± 2.52
NIATx-TI Framework
19.11
± 62.68
Adoption - The Percentage of Counselors Using A-CHESS Will be Assessed Via the Organizational Survey and A-CHESS LogsSecondary· Collected twice during study; starting M22 - 31 and M35-44
Organizational survey will be completed by a member of the management team two times during the project (organizational baseline, end of the intervention)
Group
Value
95% CI
TAU/Control
24
NIATx-TI Framework
84
A-CHESS/NIATx Implementation Fidelity (Survey)Secondary· Collected twice during study; approx. M14 - 25 and M32 - 43
Survey data on participating organizations' fidelity to the NIATx Technology Implementation (NIATx-TI) process. The Implementation Fidelity survey is a 13 item questionnaire using a 4-point scale where 0 = Not True and 4 = True. Scores range from 0-52. Higher scores indicate greater implementation fidelity.
Survey 2
Group
Value
95% CI
TAU/Control
2.26
± 0.55
NIATx-TI Framework
2.91
± 0.51
Survey 3
Group
Value
95% CI
TAU/Control
2.20
± 0.63
NIATx-TI Framework
2.91
± 0.55
Organizational Readiness of Participating Organizations as Assessed by Organizational Change Manager (Survey)Secondary· Collected twice during study; approx. M14 - 25 and M32 - 43
Survey data on the organizational readiness of participating organizations. Organizational Readiness (as measured by Organizational Change Manager) - 5 categories from Not True (0) to True (3) and Don't Know (No score). Scores range from 0-66. Higher scores indicate greater readiness for change.
Survey 2
Group
Value
95% CI
TAU/Control
2.99
± 0.58
NIATx-TI Framework
3.17
± 0.50
Survey 3
Group
Value
95% CI
TAU/Control
2.73
± 0.75
NIATx-TI Framework
3.28
± 0.40
Financial Resource Availability (Survey)Secondary· Collected twice during study; starting M22 - 31 and M35-44
Survey data on how the organization's financial resource availability affects A-CHESS implementation. Scored the availability of financial resources on a 5-point scale from 0= Not Ture to 4= True. Scores range from 0-28. Higher score indicates greater availability of resources.
Survey 1
Group
Value
95% CI
TAU/Control
2.68
± 0.73
NIATx-TI Framework
3.41
± 0.57
Survey 2
Group
Value
95% CI
TAU/Control
2.77
± 0.83
NIATx-TI Framework
3.13
± 0.87
Difference in Number of Admissions in Rural vs. Urban LocationSecondary· Collected during months 7, 18, 30, and 42, month 42 reported
Statistical analysis of organizational traits will be done by calculating the difference in number of admissions in rural vs. urban location. The number of clinics located in a rural area was counted. The number of clinics in an urban location were counted.
Group
Value
95% CI
TAU/Control
1
NIATx-TI Framework
3
TAU/Control
17
NIATx-TI Framework
17
TAU/Control
1
NIATx-TI Framework
1
Sponsor's own description
This research will test a technology adoption framework to increase use of the A-CHESS smartphone app. The project, based in Iowa, will compare a control condition (using a typical product training approach to software implementation that includes user tutorials and instruction on administrative and clinical protocols, followed by access to on-line support) to the typical product training combined with NIATx-TI.
Terms - A-CHESS: Addiction Comprehensive Health Enhancement Support System NIATx-TI: Network for the Improvement of Addiction Treatment-Technology Implementation
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Substance Use Disorders
Currently open trials in the same condition.
NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC
· NA
· recruiting
NCT07529327 — Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups an
· NA
· recruiting
NCT07281261 — tAN for Substance Use Disorder
· NA
· recruiting
NCT07210268 — Temporal Interference Methods for Addiction Treatment
· NA
· recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD
· NA
· recruiting
Other University of Wisconsin, Madison trials
Trials by the same sponsor.
NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts
· Phase 1
· recruiting
NCT07278466 — The COMParing App Support Strategies Study
· NA
· recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin
· NA
· enrolling by invitation
NCT07470723 — The ORIGIN-FH Study
· NA
· recruiting
NCT06975657 — Well-being Skills for Reentry
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03954184.